Impact of Nuclear Factor Erythroid 2–Related Factor 2 in Hepatocellular Carcinoma: Cancer Metabolism and Immune Status

Norifumi Iseda, Shinji Itoh, Tomoharu Yoshizumi, Yukinari Tomiyama, Kyohei Yugawa, Masahiro Shimokawa, Tomonari Shimagaki, Huanlin Wang, Takeshi Kurihara, Yoshiyuki Kitamura, Yoshihiro Nagao, Takeo Toshima, Noboru Harada, Kenichi Kohashi, Shingo Baba, Kousei Ishigami, Yoshinao Oda, and Masaki Mori

We examined phosphorylated nuclear factor erythroid 2–related factor 2 (P-NRF2) expression in surgically resected primary hepatocellular carcinoma (HCC) and investigated the association of P-NRF2 expression with clinicopathological features and patient outcome. We also evaluated the relationship among NRF2, cancer metabolism, and programmed death ligand 1 (PD-L1) expression. In this retrospective study, immunohistochemical staining of P-NRF2 was performed on the samples of 335 patients who underwent hepatic resection for HCC. Tomography/computed tomography using fluorine-18 fluorodeoxyglucose was performed, and HCC cell lines after NRF2 knockdown were analyzed by array. We also analyzed the expression of PD-L1 after hypoxia inducible factor 1α (HIF1A) knockdown in NRF2-overexpressing HCC cell lines. Samples from 121 patients (36.1%) were positive for P-NRF2. Positive P-NRF2 expression was significantly associated with high alpha-fetoprotein (AFP) expression, a high rate of poor differentiation, and microscopic intrahepatic metastasis. In addition, positive P-NRF2 expression was an independent predictor for recurrence-free survival and overall survival. NRF2 regulated glucose transporter 1, hexokinase 2, pyruvate kinase isoenzymes L/R, and phosphoglycerate kinase 1 expression and was related to the maximum standardized uptake value. PD-L1 protein expression levels were increased through hypoxia-inducible factor 1α after NRF2 overexpression in HCC cells. Conclusions: Our large cohort study revealed that P-NRF2 expression in cancer cells was associated with clinical outcome in HCC. Additionally, we found that NRF2 was located upstream of cancer metabolism and tumor immunity. (Hepatology Communications 2022;6:665–678).

Hepatocellular carcinoma (HCC) is a common cancer worldwide. Hepatic resection is a safe and effective treatment in patients with HCC, and preserves liver function. However, the proportion of patients who develop intrahepatic recurrence remains high.

Abbreviations: AFP, alpha-fetoprotein; CI, confidence interval; 18F-FDG, fluorine-18 fluorodeoxyglucose; G6Pase, glucose-6–phosphatase; GLUT1, glucose transporter 1; HCC, hepatocellular carcinoma; HIF1α, hypoxia inducible factor 1α; HK2, hexokinase 2; HR, hazard ratio; IFN-γ, interferon gamma; IHC, immunohistochemistry; IQR, interquartile range; mRNA, messenger RNA; NRF2, nuclear factor erythroid 2–related factor 2; OS, overall survival; PCR, polymerase chain reaction; PD-L1, programmed death ligand 1; PET/CT, positron emission tomography/computed tomography; PGK1, phosphoglycerate kinase 1; PKLR, pyruvate kinase isoenzymes L/R; P-NRF2, phosphorylated nuclear factor erythroid-derived 2–like 2; RFS, recurrence-free survival; SUVmax, standardized uptake value maximum.

Received May 12, 2021; accepted September 16, 2021.
Addtional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1002/hep4.1838/suppinfo.
Norifumi Iseda and Shinji Itoh contributed equally to this work. Supported by the Japan Society for the Promotion of Science (19K09198 and JP-16K10576). © 2021 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
the down-regulation of a series of genes involved in the pentose phosphate pathway, which is a branch of glycolytic metabolism.\(^8\)

The recent large phase 3 study IMbrave150 demonstrated improvements in HCC prognosis for atezolizumab, an anti–programmed cell death ligand 1 (PD-L1) antibody + bevacizumab, an angiogenesis inhibitor, compared with sorafenib.\(^9\) Recently, we revealed that PD-L1 expression in cancer cells was associated with poor clinical outcome in 418 patients with HCC, and a high maximum standardized uptake value (SUV\(_{\text{max}}\)) on fluorine-18 fluorodeoxyglucose (\(^{18}\text{F}-\text{FDG}\)) positron emission tomography/computed tomography (PET/CT) was associated with high PD-L1 expression in patients with HCC.\(^{10,11}\) High NRF2 expression was related to high PD-L1 expression in various cancers.\(^{12,13}\) However, the relationship among NRF2 protein expression, \(^{18}\text{F}-\text{FDG}\) PET/CT, and PD-L1 protein expression in HCC is unclear.

In this study, we examined the prognostic impact of NRF2 protein expression in patients with HCC and the association of NRF2 with PD-L1 expression and the SUV\(_{\text{max}}\) on \(^{18}\text{F}-\text{FDG}\) PET/CT.

**Materials and Methods**

**CELL CULTURE AND REAGENTS**

HuH7 and Hep3B cells were obtained from the American Type Culture Collection (Manassas, VA). HuH7 and Hep3B were cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum, 100 IU/mL penicillin, and 100 μg/mL streptomycin at 37°C in 10% CO\(_2\). Antibodies against phosphorylated NRF2 (P-NRF2), NRF2, PD-L1, and HIF1α were purchased from Abcam (Cambridge, United Kingdom). β-actin antibody was obtained from Sigma-Aldrich (St. Louis, MO). Stealth RNA interference (RNAi; Thermo Fisher Scientific, Waltham, MA; GE Healthcare Dharmacon, Lafayette, CO) was used to knock down HIF1A.

**GENERATION OF NRF2-EXPRESSING CELLS AND NFE2L2 AND HIF1A GENE SUPPRESSION**

NRF2 plasmid (NM_006164; Origene) was transfected into HCC cells using the jetPRIME kit (Polyplus Transfection). An empty vector (pCMV6-Entry Vector; Origene) was also transfected into HCC cells as a control. Forty-eight hours after transfection, HCC cells were selected with 500 μg/mL G418 (Sigma-Aldrich). The limiting dilution method was used for the isolation of single-cell clones from the transfected HCC cells. Selected single cells were placed in each well of culture plates, and the clonal populations growing from each cell were isolated. HCC cells were checked for mycoplasma infection before and after transfection, and all were negative.

We used NFE2L2-knockdown or HIF1A-knockdown cells. Transient gene suppression was achieved in HuH7 and Hep3B HCC cells using Stealth RNAi. Cells were prepared in complete...
growth medium without antibiotics (50,000 cells per 500 μL; 30%-50% confluency 24 hours after plating). Then reverse transfection was performed using 10 nM Stealth RNAi with Opti-MEM I Reduced Serum Medium and Lipofectamine RNAiMAX for 24 hours at 37°C in a CO₂ incubator.

**WESTERN BLOTTING**

Samples were lysed in lysis buffer containing 50 mmol/L Tris HCl (pH 6.8) and 10% sodium dodecyl sulfate, and the protein concentration of each sample was determined using a Bio-Rad Protein Assay kit (Hercules, CA). Samples were heated at 95°C for 5 minutes and subjected to electrophoresis using SuperSep Ace 12% gels (Fujifilm) at 20 mA for 80 minutes. The Trans-Blot Turbo Transfer System (Bio-Rad) was used to transfer proteins onto polyvinylidene fluoride membranes (Bio-Rad). Primary and secondary antibodies were diluted in iBind solution (Invitrogen, Waltham, MA). Primary antibodies were anti-rabbit NRF2 antibody (dilution 1:1,000; Abcam), anti-rabbit P-NRF2 (dilution 1:1,000; Abcam), anti-rabbit HIF1α (dilution 1:1000; Abcam), anti-rabbit PD-L1 (dilution 1:500; Abcam), and anti-rabbit glyceraldehyde 3-phosphate dehydrogenase (GAPDH; dilution 1:5,000; GeneTex, Irvine, CA). Secondary antibody was goat anti-rabbit immunoglobulin G (IgG) H&L (1:5,000; Abcam) and anti-mouse IgG H&L (1:5,000; Abcam). The membranes were incubated in iBind solution (Invitrogen) with primary and secondary antibodies. Each blot was incubated with Chemiluminescent HRP Antibody Detection Reagent (Denville Scientific, Holliston, MA) and imaged using Amersham Imager 600 (GE Healthcare).

**IMMUNOHISTOCHEMICAL STAINING**

Immunohistochemical (IHC) staining for P-NRF2 and PD-L1 was performed on 4-μm-thick formalin-fixed and paraffin-embedded sections. Sections were first deparaffinized and then blocked with 10% normal goat serum. The tissue sections were incubated with P-NRF2 primary antibody (rabbit monoclonal; 1:100; clone #EP1809Y; Abcam) at 4°C overnight. Stained slides were scanned using the NanoZoomer (Hamamatsu Photonics KK, Japan). IHC data for P-NRF2 staining were evaluated by three experienced researchers (N.I., K.Y., and K.K.) who were blinded to the clinical statuses of the patients. The final assessments were achieved by consensus. The staining intensities of cancer cells with nuclear staining for P-NRF2 were scored as 0 (negative), 1 (weak), 2 (moderate), or 3 (strong). Tumor cell staining was scored as 0 (0%), 1 (1%-25%), 2 (26%-50%), 3 (51%-75%), or 4 (76%-100%). IHC for PD-L1 was performed as described previously. We set the cutoff of PD-L1 positivity at 1%.

**IMMUNOFLUORESCENCE**

Treated cells were first incubated with 4% paraformaldehyde for 10 minutes at room temperature and then blocked with 5% goat serum for 60 minutes at room temperature. Cells were then incubated with primary antibodies (P-Nrf2, dilution 1:2,000, Abcam; PD-L1, dilution 1:1,000, Cell Signaling Technology, Danvers, MA) at 4°C overnight, followed by incubation with Alexa Fluor 597-conjugated or Alexa Fluor 488-conjugated secondary antibodies (1:250, Thermo Fisher Scientific) for 1 hour at room temperature. Cells were then stained with diamidino-phenylindole for 10 minutes at room temperature. After washes, cells were observed using a fluorescence microscope (Biorevo BZ-9000; Keyence, Osaka, Japan).

**RNA EXTRACTION, REAL-TIME POLYMERASE CHAIN REACTION, AND POLYMERASE CHAIN REACTION ARRAY**

Total RNA was extracted from cells using the Maxwell RSC simplyRNA Cells Kit (Promega, Madison, WI). Quantitative real-time polymerase chain reaction (PCR) was performed using the ABI Prism 7000 Sequence Detection System (Applied Biosystems, Foster City, CA). The primers used in this study were as follows: glucose transporter 1 (GLUT1) forward 5’-CTGCAACGGCTTAGACTTCGAC-3’ and reverse 5’-TCTCTGGGT-TACAGGATCACA-3’; hexokinase 2 (HK2) forward 5’-AACAG CCTGACGAGGATCACA-3’; hexokinase 2 (HK2) forward 5’-AACAG CCTGACGAGGATCACA-3’ and reverse 5’-AGGTCAACTCCTCTCGCCG-3’; phosphoglycerate kinase 1 (PGK1) forward 5’-ATGCTG AGGCTGTCACCCG-3’ and reverse 5’-CAC
AGCAAGTGCGAGTCTCC-3'; and pyruvate kinase L/R (PKLR) forward 5'-TGGGAAAACCTGGTGGGATGGATG-3' and reverse 5'-GAAGGAAAGCAGCAGGGGATTGAC-3'. Relative expression was calculated using the 2^−ΔΔCt method. Each sample was analyzed in triplicate. PCR array was performed using RT² Profiler PCR Arrays (Qiagen, Hilden, Germany).

**DETERMINATION OF CELL VIABILITY**

Cell viability was evaluated using the CellTiterGlo luminescent cell viability assay kit (Promega), which determines cellular viability using adenosine triphosphate levels.

**TRANSWELL MIGRATION AND INVASIVENESS ASSAY**

Cell migration and invasiveness assays used Falcon Permeable Supports for 24-well plates with an 8.0-µm Transparent PET Membrane (Corning, Corning, NY). Cell invasion assays were performed using 15 µL Matrigel Matrix (5 mg/mL) (Corning) to coat the bottom of each Transwell insert. Stained cells using Diff-Quik (JACLaS, Tokyo, Japan) on the Transwell membrane surface were counted in five randomly selected fields at ×200 magnification and quantified using Image J software (https://imagej.net/). The experiment was repeated 3 times.

**TISSUE SAMPLES**

A total of 355 patients with HCC who underwent hepatic resection at the Department of Surgery and Science, Kyushu University Hospital, between January 2002 and December 2018, were enrolled in this study. The details of our surgical techniques and patient selection criteria for hepatic resection in HCC were previously reported. No patients received preoperative treatment. Patients were followed up as outpatients every 1 to 3 months after discharge. Dynamic computed tomography was performed by radiologists every 3 months, and magnetic resonance imaging was performed if recurrence was suspected. Clinical information and follow-up data were obtained from medical records. This study was approved by the ethics committee of Kyushu University (approval code: 2020-745).

**18F-FDG PET/CT**

In each patient, 185 MBq FDG was intravenously administered after fasting for at least 4 hours. Scans were conducted from the middle of the thigh to the top of the skull 60 minutes after FDG administration. FDG-PET/CT images were obtained using an integrated PET/CT scanner (Discovery STE; GE Medical Systems, Milwaukee, WI) or Biograph mCT (Siemens Medical Solutions, Erlangen, Germany). All emission scans were performed in the 3-dimensional mode, and the acquisition time per bed position was 3 minutes for Discovery STE and 2 minutes for Biograph mCT. We reconstructed PET images using the ordered subset expectation maximization method (VUE Point Plus) with two full iterations of 28 subsets for the Discovery STE and iterative True-X algorithm, and time-of-flight (Ultra HD-PET) with two full iterations of 21 subsets. The True-X algorithm incorporates an additional specific correction for the point-spread function. The FWHM values of the Discovery STE and Biograph mCT were 5.2 and 4.4 mm, respectively. A low-dose 16-slice CT image (tube voltage 120 kV; effective tube current 30-250 mA; Discovery STE) and a low-dose 32-slice CT image (tube voltage 120 kV; angular and longitudinal dose modulation; CAREDose4D; Biograph mCT) from the vertex to the proximal thigh were performed for attenuation correction and to determine the precise anatomical location of the lesions before the acquisition of PET images. CT scans were reconstructed by filtered back projection into 512 × 512 pixel images with a slice thickness of 5 mm to match the PET scan. FDG uptake in lesions was evaluated using SUVmax and calculated using a dedicated workstation for each scanner. The best cutoff values of these markers were determined by the receiver operating characteristic curve.

**STATISTICAL ANALYSIS**

Standard statistical analyses were used to evaluate descriptive statistics, such as medians, frequencies, and percentages. Continuous variables without a normal distribution and variables, such as the data obtained using cell lines, were compared using the Mann-Whitney U test. A logistic regression analysis was performed to identify variables for P-NRF2 expression. Categorical variables were compared using the χ² test or Fisher’s exact test. Survival data were used to establish a univariate Cox proportional hazards
model. Covariates that were significant at \( P < 0.05 \) were included in the multivariate Cox proportional hazards model. Cumulative overall survival (OS) and recurrence-free survival (RFS) rates were calculated using the Kaplan-Meier method, and differences between the curves were evaluated using the log-rank test. Differences were considered significant at \( P < 0.05 \). All statistical analyses were performed using JMP15 software (SAS Institute Inc., Cary, NC).

Results

P-NRF2 EXPRESSION AND CLINICOPATHOLOGICAL CHARACTERISTICS IN HCC

To estimate the expression levels of P-NRF2 in HCC, we performed IHC staining of 335 HCC tissues. The cancer cells showed nuclear staining for P-NRF2 (Fig. 1). We used Q score to quantify expression, which is the sum of the intensity and proportion scores and ranges from 0 to 7.\(^{16}\) The median P-NRF2 Q score was 3. A Q score < 4 was considered negative and a Q score \( \geq 4 \) was considered positive. The associations between P-NRF2 expression and clinicopathological characteristics in patients with HCC were evaluated. Table 1 summarizes the clinicopathological factors of patients with high and low P-NRF2 expression. A total of 121 (36.1\%) patients were positive for P-NRF2. P-NRF2 protein expression was higher in patients with high AFP (\( P = 0.0229 \)), high rates of poorly differentiated HCC (\( P < 0.0001 \)), and microscopic intrahepatic metastasis (\( P = 0.0244 \)).

P-NRF2 EXPRESSION AND SUVMAX

Next, we assessed the association between IHC staining for P-NRF2 and SUVmax in 171 patients with HCC. P-NRF2-positive expression in cancer cells was associated with a significantly high SUVmax compared with P-NRF2-negative expression (P-NRF2-positive: median 4.89, interquartile range [IQR] 3.66-6.73; P-NRF2-negative: median 3.38, IQR 2.91-4.21; \( P < 0.0001 \)) (Fig. 2).

P-NRF2 EXPRESSION AND PATIENT SURVIVAL

Next, we assessed whether P-NRF2 expression was related to postoperative survival using the Kaplan-Meier method. The 10-year RFS and OS rates were 19.0\% and 31.5\%, respectively, in patients with high P-NRF2 expression, and 24.9\% and 60.9\%, respectively, in patients with low P-NRF2 expression (Fig. 3A,B). Patients with high P-NRF2 expression had a significantly worse prognosis than those with low P-NRF2 expression for RFS (log rank \( P < 0.001 \)) and OS (log rank \( P < 0.0001 \)) (Fig. 3A,B). Among the 193 cases with recurrence, the rate of postoperative intrahepatic

---

**FIG. 1.** IHC staining of P-NFR2 in patients with HCC.
metastasis with multiple nodules was higher in patients with high P-NRF2 expression than in those with low P-NRF2 expression (22 of 76 [29.0%] vs. 11 of 117 [9.4%]; P = 0.0005). There was no significant difference in the rate of distant metastasis between high and low P-Nr2 expression group (11 of 76 [14.5%] vs. 12 of 117 [10.3%]; P = 0.3810). The rate of repeat hepatic resection or local ablation therapy for intrahepatic recurrence tended to be higher in patients with low P-NRF2 expression than in those with high P-NRF2 expression (36 of 76 [47.4%] vs. 70 of 117 [59.8%]; P = 0.0892). The rate of using molecular target agents was higher in patients with high P-NRF2 expression than in those with low P-NRF2 expression (6 of 76 [7.9%] vs. 2 of 117 [1.7%]; P = 0.0365).

### Table 1. Association Between P-NRF2 and Patient Clinicopathological Factors

| Characteristic                  | P-NRF2-Low (n=214) | P-NRF2-High (n = 121) | P Value |
|---------------------------------|--------------------|----------------------|---------|
| Age (years)                     | 70 (64-77)         | 69 (63-76)           | 0.8083  |
| Sex, male/female                | 154/60             | 87/34                | 0.9904  |
| BMI (kg/m²)                     | 22.96 (20.79-25.35)| 23.67 (21.68-25.85)  | 0.1614  |
| Diabetes mellitus               | 71 (33.1%)         | 38 (31.4%)           | 0.7394  |
| HBs-Ag-positive                 | 37 (17.2%)         | 20 (16.5%)           | 0.8587  |
| HCV-Ab-positive                 | 108 (50.4%)        | 58 (47.9%)           | 0.6560  |
| Albumin (g/dL)                  | 4.0 (3.8-4.2)      | 3.9 (3.7-4.3)        | 0.1081  |
| Child-Pugh classification, grade B | 6 (2.8%)           | 5 (4.1%)             | 0.5346  |
| AFU (ng/mL)                     | 8.9 (4.0-48.1)     | 16.9 (4.8-417)       | 0.0229  |
| DCP (mAU/mL)                    | 99 (25-418)        | 105 (27-793)         | 0.3388  |
| Tumor size (cm)                 | 3.2 (2.4-4.8)      | 3.4 (2.3-5.5)        | 0.5961  |
| Solitary/multiple               | 178/36             | 98/23                | 0.6139  |
| BCLC staging, B or C            | 27 (12.6%)         | 22 (18.1%)           | 0.1661  |
| Gross classification, single nodular type | 129 (60.3%)  | 80 (66.1%)           | 0.2896  |
| Poorly differentiated           | 40 (18.6%)         | 48 (39.6%)           | < 0.0001|
| Microscopic vascular invasion   | 62 (28.9%)         | 34 (28.1%)           | 0.8652  |
| Microscopic intrahepatic metastasis | 22 (10.2%)      | 23 (19.0%)           | 0.0244  |
| F3 or F4                        | 86 (40.1%)         | 52 (42.9%)           | 0.6184  |

Note: The data are presented as n (%) or median (IQR). Abbreviations: BCLC, Barcelona Clinic Liver Cancer; BMI, body mass index; DCP, des-gamma-carboxyprothrombin; HBs-Ag, hepatitis B surface antigen; and HCV-Ab, hepatitis C virus antibody.

### UNIVARIATE AND MULTIVARIATE ANALYSES OF PROGNOSTIC FACTORS FOR RFS AND OS

Table 2 lists the univariate and multivariate analyses results associated with RFS and OS after hepatic resection in patients with HCC. Cox proportional hazards regression model with multivariate analysis showed that P-NRF2-positive expression in cancer cells was associated with significantly worse RFS and OS (hazard ratio [HR] 1.95, 95% confidence interval [CI] 1.43–2.66, P < 0.0001 and HR 1.91, 95% CI 1.23–2.95, P = 0.0037, respectively).

### ASSOCIATION OF NRF2 EXPRESSION AND CANCER METABOLISM

We investigated the association of NRF2 and metabolism in Hep3B and HuH7 HCC cell lines, because there is a clinical relationship between P-NRF2 and metabolism. Messenger RNA (mRNA) expression in NRF2-overexpressing Hep3B cell and control Hep3B cell was analyzed using RNA arrays. A heatmap showed distinct differences in mRNA expression in NRF2-overexpressing cells compared with mRNA expression in control cells. Compared
with control cells, glycolysis-related mRNA was upregulated in NRF2-overexpressing cells (Fig. 4A). 

GLUT1, HK2, PKLR, and PGK1 expression was next assessed using quantitative real-time PCR in NRF2-overexpressing cells and control cells. GLUT1, HK2, PKLR, and PGK1 expression was higher in NRF2-overexpressing cells (Fig. 4B,C). We next investigated the proliferation of NRF2-overexpressing cells using the CellTiterGlo luminescent cell viability assay kit (Promega). The results showed that NRF2-overexpressing cells had a significantly higher proliferation rate compared with the control cells (Supporting Fig. S1A). Moreover, we performed Transwell assays to investigate the influence of NRF2 on migration and invasion. Compared with the control, migration and invasion was up-regulated in NRF2-overexpressing cells (Supporting Fig. S1B,C).

**P-NRF2 REGULATED PD-L1 EXPRESSION THROUGH HIF1α**

Previously, we reported a relationship between metabolic activity and immune status and demonstrated that PD-L1 expression in cancer cells was associated with clinical outcome in patients with HCC. Using these previous data of PD-L1 expression, the relationship between P-NRF2 and PD-L1 expression was examined in 335 patients with HCC. Thirty-seven of 121 (30.6%) cases with positive expression of P-NRF2 showed positive expression of PD-L1, and 34 of 214 (15.9%) cases with negative expression of P-NRF2 showed negative expression of PD-L1. This indicated that P-NRF2 expression was significantly correlated with PD-L1 protein levels in HCC ($P = 0.0016$).

NRF2 directly regulates the expression of HIF1α in various cancer types. Increased HIF1 levels were associated with increased PD-L1 expression. To test whether NRF2 expression regulated PD-L1 expression through HIF1α-regulated PD-L1 expression in HCC cell lines, we confirmed NRF2, HIF1α, and PD-L1 protein levels in control and NRF2-overexpressing HCC cell lines by western blot analysis. We found that HIF1α and PD-L1 protein levels were increased in NRF2-overexpressing cells with interferon gamma (IFN-γ) (Fig. 5A). Next, we investigated whether NRF2 increased PD-L1 expression via HIF1α. HIF1α expression was knocked down and PD-L1 expression was examined in NRF2-overexpressing cells. In HIF1α knockdown cells, PD-L1 expression was reduced compared with the control with IFN-γ (Fig. 5B). We also found that PD-L1 protein expression was higher in NRF2 overexpression cells compared with control cells using immunofluorescent double staining (Supporting Fig. S2). Specifically, it was considered that NRF2 increased the expression of PD-L1 through HIF1α.

**Discussion**

In the present study, we analyzed P-NRF2 expression in patients with HCC who had undergone hepatic resection. A high P-NRF2 expression pattern was a significantly poor prognostic factor. NRF2
regulates glucose metabolism, and high NRF2 expression in cancer cells was associated with high SUVmax. Additionally, we showed that NRF2 expression in cancer cells regulated PD-L1 expression through HIF1α.

Several recent reports have evaluated the prognostic impact of NRF2 protein expression in various cancers.(19,20) Kitano et al. showed that high NRF2 expression was significantly associated with cell

### TABLE 2. UNIVARIATE AND MULTIVARIATE ANALYSES OF FACTORS RELATED TO RFS AND OS IN PATIENTS WITH HCC WHO HAD UNDERGONE HEPATIC RESECTION (COX PROPORTIONAL HAZARDS ANALYSIS)

| Factor                        | RFS Univariate Analysis | RFS Multivariate Analysis | OS Univariate Analysis | OS Multivariate Analysis |
|-------------------------------|-------------------------|---------------------------|------------------------|--------------------------|
|                              | HR (95% CI)             | PValue                    | HR (95% CI)            | PValue                    |
| Age (years)                  | 1.008 (0.995-1.022)     | 0.2126                    | 1.025 (1.005-1.048)    | 0.0161                    |
|                              |                         |                           | 1.030 (1.005-1.057)    | 0.0180                    |
| Sex                          | Male 1.351 (0.965-1.892) | 0.858 (0.558-1.320)       | 0.4886                 |
|                              | Female 0.0796           | 0.928 (0.594-1.449)       | 0.7439                 |
| Diabetes mellitus            | Positive 0.947 (0.698-1.285) | 0.7273                   | 0.758 (0.442-1.299)    | 0.3146                    |
|                              | Negative 0.7273         |                           |                        |
| HBsAg                        | Positive 0.909 (0.628-1.314) | 0.6130                   | 0.449 (1.840-1.479)    | 0.4489                    |
|                              | Negative 0.4489         |                           | 0.0063                 |
| Albumin                      | 0.526 (0.379-0.735)     | 0.559 (0.398-0.790)       | 0.345 (0.219-0.549)    | 0.456 (0.268-0.782)       |
|                              | 0.0001                  | 0.0009                    | < 0.0001              | 0.0040                    |
| Child-Pugh classification    | B 1.227 (0.576-2.614)   | 2.122 (0.924-4.872)       |                        |
|                              | A 0.5953                | 0.0757                    | 0.037                 |
| AFP                          | 1.000 (1.000-1.000)     | 0.00001                   | 1.000 (1.000-1.000)    | 0.999 (0.999-1.000)       |
|                              | < 0.0001                | 0.0079                    | 0.0050                | 0.2074                    |
| DCP                          | 1.000 (1.000-1.000)     | 0.999 (0.999-1.000)       | 1.000 (1.000-1.000)    | 0.999 (0.999-1.000)       |
|                              | 0.0063                  | 0.6907                    | 0.0392                | 0.2037                    |
| Tumor size                   | 1.101 (1.048-1.153)     | 1.021 (0.947-1.093)       | 1.124 (1.055-1.190)    | 1.059 (0.945-1.181)       |
|                              | < 0.0001                | 0.5678                    | 0.0001                | 0.3040                    |
| Macrosopic tumor number      | Multiple 2.209 (1.560-3.070) | 1.314 (0.775-2.227)       | 2.061 (1.313-3.234)    | 2.190 (0.975-4.914)       |
|                              | Single 0.00001          | 0.3106                    | 0.0017                | 0.0573                    |
| BCLC staging                 | B or C 2.972 (2.091-4.224) | 1.615 (0.890-2.932)       | 3.698 (2.399-5.700)    | 3.537 (1.591-7.860)       |
|                              | O or A 0.00001          | 0.1148                    | < 0.0001              | 0.0019                    |
| Poorly differentiated        | Present 1.565 (1.149-2.131) | 0.961 (0.673-1.372)       | 1.859 (1.232-2.804)    | 1.004 (0.604-1.669)       |
|                              | Absent 0.0044           | 0.8286                    | 0.0031                | 0.9854                    |
| Microscopic vascular invasion| Present 1.447 (1.071-1.955) | 1.294 (0.920-1.818)       | 2.016 (1.352-3.004)    | 1.498 (0.927-2.423)       |
|                              | Absent 0.0160           | 0.1378                    | 0.0006                | 0.0986                    |
| Microscopic intrahepatic     | Present 3.379 (2.318-4.924) | 2.144 (1.299-3.538)       | 3.379 (2.107-5.416)    | 2.592 (1.301-5.163)       |
| metastasis                   | Absent < 0.0001         | 0.0028                    | < 0.0001              | 0.0067                    |
| Microscopic liver fibrosis   | F3 or F4 1.292 (0.972-1.716) | 1.519 (1.019-2.263)       | 1.891 (1.214-2.946)    | 0.0048                    |
|                              | F0, F1, or F2 0.0786    | 0.0399                    | 0.0048                |
| P-NRF2                       | High 1.787 (1.334-2.395) | 1.952 (1.430-2.664)       | 2.270 (1.521-3.388)    | 1.910 (1.234-2.955)       |
|                              | Low < 0.0001           | < 0.0001                   | < 0.0001              | 0.0037                    |

Abbreviations: BCLC, Barcelona Clinic Liver Cancer; DCP, des-gamma carboxyprothrombin; HBsAg, hepatitis B surface antigen; and HCV-Ab, hepatitis C virus antibody.
High expression of NRF2 and its downstream effectors promoted migration and invasion of cancer cells. Furthermore, NRF2 could mediate chemoresistance and radioresistance in tumor therapy. In this study, we demonstrated that high P-NRF2 expression was associated with high AFP, poor differentiation, and microscopic intrahepatic metastasis. Our findings are consistent with previous results. The present report used a large sample size to reveal the critical stratification of prognosis in patients with HCC on the basis of P-NRF2 expression.

In the current study, we observed that GLUT1, HK2, PKLR, and PGK1 mRNA expression was higher in NRF2-overexpressing cells, and NRF2 was related to...
glucose metabolism. Several recent studies suggested that NRF2 regulates cancer metabolism in various types of cancer. (19,25) The phophatidylinositol 3-kinase-protein kinase/ Akt pathway augments the nuclear accumulation of NRF2 and enables NRF2 to promote glucose metabolic activities that support cell proliferation in addition to enhancing cytoprotection. (8) HIF1α was also shown to have critical roles in the regulation of glycolysis metabolism, and up-regulates the expression of GLUT1 and HK2. (26–28) Collectively, NRF2 and HIF1α reinforce the malignant behavior of HCC by up-regulating proliferation and glucose metabolism.

The molecular mechanisms involved in FDG imaging relate to its uptake by GLUT1 and metabolism by HK and glucose-6-phosphatase (G6Pase). FDG accumulates in malignant cells through GLUT1 transportation and HK phosphorylation. (29) G6Pase, a gluconeogenesis enzyme strongly expressed in the liver, (30) counteracts HK phosphorylation by converting glucose-6-phosphate to glucose. High G6Pase levels therefore reduce FDG accumulation by accelerating the conversion of FDG-6-phosphate to FDG-6-phosphate to FDG, leading to its release from cells. (31) Low GLUT1 and high G6Pase expression contribute to low FDG uptake in HCC tumors, preventing efficient tumor detection. A pattern of high GLUT1 uptake, and promoted a high SUVmax.

Fig. 4. Relationship between NRF2 and metabolism in HCC. (A) Heatmap shows distinct differences in mRNA expression in NRF2-high cells and NRF2-low cells. (B, C) GLUT1, HK2, PKLR, and PGK1 expression were assessed using quantitative real-time PCR in NRF2-overexpressing cells and control cells. Abbreviations: ACLY, ATP Citrate Lyase; ACO1, Aconitase 1; ACO2, Aconitase 2; ACTB, Actin Beta; AGL, Amylo Alpha-1, 6-Glucosidase, 4-Alpha-Glucanotransferase; ALDOB, Aldolase, Fructose-Bisphosphate B; ALDOCS, Aldolase, Fructose-Bisphosphate C; B2M, Beta-2-Microglobulin; BPGM, Bisphosphoglycerate Mutase; CS, Citrate Synthase; Ctrl, control; DLAT, Dihydrolipoamide S-Acetyltransferase; DLD, Dihydrolipoamide Dehydrogenase; DLST, Dihydrolipoamide S-Succinytranferase; ENO1, Enolase 1; ENO1, Enolase 1; ENO3, Enolase 3; FBP1, Fructose-Bisphosphatase 1; FBP2, Fructose-Bisphosphatase 2; FHI, Fumarate Hydratase; G6PC, Glucose-6-Phosphatase Catalytic Subunit; G6PC3, Glucose-6-Phosphatase Catalytic Subunit 3; G6PD, Glucose-6-Phosphate Dehydrogenase; GALT, Galactose Mutarotase; GAPDH, Glyceraldehyde-3-Phosphate Dehydrogenase; GBE1, 1,4,5-Glucone-Branching Enzyme; GCK, Glucokinase; G6P, Glucose-6-Phosphate Isomerase; GSK3A, Glycogen Synthase Kinase 3 Alpha; GSK3B, Glycogen Synthase Kinase 3 Beta; GYS1, Glycogen Synthase 1; GYS2, Glycogen Synthase 2; H6PD, Hexose-6-Phosphate Dehydrogenase/Glucose-1-Dehydrogenase; HK3, Hexokinase 3; HPRT1, Hypoxanthine Phosphoribosyltransferase 1; IDH1, Isocitrate Dehydrogenase (NAD(+)) 1; IDH2, Isocitrate Dehydrogenase (NAD(+)) 2; IDH3A, Isocitrate Dehydrogenase (NAD(+)) 3 Catalytic Subunit Alpha; IDH3B, Isocitrate Dehydrogenase (NAD(+)) 3 Non-Catalytic Subunit Gamma; MDH1, Malate Dehydrogenase 1; MDH1B, Malate Dehydrogenase 1B; MDH2, Malate Dehydrogenase 2; PC, Pyruvate Carboxylase; PCK1, Phosphoenolpyruvate Carboxykinase 1; PCK2, Phosphoenolpyruvate Carboxykinase 2; PDK1, Pyruvate Dehydrogenase Kinase 1; PDK2, Pyruvate Dehydrogenase Kinase 2; PDK3, Pyruvate Dehydrogenase Kinase 3; PDK4, Pyruvate Dehydrogenase Kinase 4; PDP2, Pyruvate Dehydrogenase Phosphatase Catalytic Subunit 2; PDPY, Pyruvate Dehydrogenase Phosphatase Regulatory Subunit; PFKL, Phosphofructokinase, Liver Type; PGAM2, Phosphoglycerate Mutase 2; PGLS, 6-Phosphogluconolactonase; PMG1, Phosphoglucomutase 1; PMG2, Phosphoglucomutase 2; PMG3, Phosphoglucomutase 3; PHKA1, Phosphorylase Kinase Catalytic Subunit Alpha 1; PHKB, Phosphorylase Kinase Catalytic Subunit Beta; PHKG1, Phosphorylase Kinase Catalytic Subunit Gamma 1; PHKG2, Phosphorylase Kinase Catalytic Subunit Gamma 2; PRPS1, Phosphoribosyl Pyrophosphate Synthetase 1; PRPS1L1, Phosphoribosyl Pyrophosphate Synthetase 1 Like 1; PRPS2, Phosphoribosyl Pyrophosphate Synthetase 2; PYGL, Glyceraldehyde-3-Phosphate Dehydrogenase, Muscle Associated; RBKS, Ribokinase; RPE, Ribulose-5-Phosphate-3-Epimerase; RPIA, Ribose-5-Phosphate Isomerase A; RPLP0, Ribosomal Protein Lateral Stalk Subunit P0; SDHA, Succinate Dehydrogenase Complex Flavoprotein Subunit A; SDHB, Succinate Dehydrogenase Complex Iron Sulfur Subunit B; SDHC, Succinate Dehydrogenase Complex Subunit C; SDHD, Succinate Dehydrogenase Complex Subunit D; SUCLA2, Succinate-CoA Ligase ADP-Forming Subunit Beta; SUCLG1, Succinate-CoA Ligase GDP/ADP-Forming Subunit Alpha; SUCLG1, Succinate-CoA Ligase GDP/ADP-Forming Subunit Alpha; TKT, Transketolase; TPI1, Triosephosphate Isomerase 1; UGP2, UDP-Glucose Pyrophosphorylase 2.
demonstrated that NRF2 protein binds the regulatory region of the PD-L1 (CD274) gene.\(^{(13)}\) HIF1 regulates PD-L1 through binding to the hypoxia response element of the CD274 promoter to activate CD274 transcription.\(^{(38)}\) NRF2 targets a functional antioxidant response element at the HIF1A locus, revealing a direct regulatory connection between two important oxygen-responsive transcription factors.\(^{(17)}\) We demonstrated that NRF2 regulated the expression of PD-L1 through HIF1α. In HCC, NRF2 might be involved in PD-L1 expression through HIF1α rather than by directly regulating PD-L1 expression.

The recent large phase 3 study IMbrave150 evaluated atezolizumab + bevacizumab versus sorafenib as the first treatment for patients with unresectable HCC. The study showed it to be statistically significant and clinically compared to sorafenib in patients with HCC.\(^{(9)}\) Sacher et al. showed that tumor PD-L1 expression was associated with an increased likelihood of tumor response to PD-L1 checkpoint inhibitors.\(^{(39)}\) We previously reported that PD-L1-positive expression in cancer cells was associated with a significantly higher SUVmax compared to PD-L1-negative expression.\(^{(10)}\) In the current study, we demonstrated that NRF2 was associated with SUVmax and PD-L1 expression in cancer cells. We speculate that patients with HCC with SUVmax-high may be more suitable for anti-PD-1/PD-L1 therapy, because patients with HCC with SUVmax-high reveal high PD-L1 expression in cancer.

In summary, our large cohort study revealed that NRF2 expression in cancer cells was associated with clinical outcome. Additionally, we found that NRF2 was located upstream of cancer metabolism and tumor immunity.

Acknowledgment: The authors thank Ms. Saori Tsurumaru, Ms. Asuka Nakamura, Ms. Yuko Kubota, and Ms. Miki Nakashima for their technical support. We also thank H. Nikki March, Ph.D., Edanz Group (https://en-author-services.edanz.com/ac), for editing a draft of this manuscript.
REFERENCES

1) Villanueva A. Hepatocellular carcinoma. N Engl J Med 2019;380:1450-1462.
2) Itoh S, Morita K, Ueda S, Sugimachi K, Yamashita Y-L, Gion T, et al. Long-term results of hepatic resection combined with intraoperative local ablation therapy for patients with multinodular hepatocellular carcinomas. Ann Surg Oncol 2009;16: 3299-3307.
3) Itoh S, Shirabe K, Taketomi A, Morita K, Harimoto N, Tsuji Y, et al. Zero mortality in more than 300 hepatic resections: validity of preoperative volumetric analysis. Surg Today 2012;42:435-440.
4) DeNicola GM, Karreth FA, Hampton TJ, Gopinathan A, Wei C, Frese K, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011;475:106-109.
5) Shimokawa M, Yoshizumi T, Itoh S, Iseda N, Sakata K, Yugawa K, et al. Modulation of Nqo1 activity intercepts anoikis resistance and reduces metastatic potential of hepatocellular carcinoma. Cancer Sci 2020;111:1228-1240.
6) Sporn MB, Liby KT. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer 2012;12:564-571.
7) Zhang M, Zhang C, Zhang L, Yang Q, Zhou S, Wen Q, et al. Nrf2 is a potential prognostic marker and promotes proliferation and invasion in human hepatocellular carcinoma. BMC Cancer 2015;15:531.
8) Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukawa T, Aburatani H, et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 2012;22:66-79.
9) Finn RS, Qin S, Ikeda M, Galle PR, Ducrueux M, Kim T-Y, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020;382:1894-1905.
10) Itoh S, Yoshizumi T, Kitamura Y, Yagawa K, Iseda N, Shimagaki T, Nagao Y, et al. Impact of metabolic activity in hepatocellular carcinoma: association with immune status and vascular formation. Hepatol Commun Mar 2021. https://doi.org/10.1002/hep4/1715. [Epub ahead of print]
11) Itoh S, Yoshizumi T, Yagawa K, Imai D, Yoshia S, Takeishi K, et al. Impact of immune response on outcomes in hepatocellular carcinoma: association with vascular formation. Hepatology 2020;72:1987-1999.
12) Best SA, De Souza DP, Kersbergen A, Policheni AN, Dayalan T, et al. Synergy between the KEAP1/NRF2 and PI3K pathways drives non-small-cell lung cancer with an altered immune microenvironment. Cell Metab 2018;27:935-943.e934.
13) Zhu BO, Tang L, Chen S, Yin C, Peng S, Li X, et al. Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy. Oncogene 2018;37:4941-4954.
14) Iseda N, Itoh S, Yoshizumi T, Yagawa K, Morinaga A, Tomiyama T, et al. ARID1A deficiency is associated with high programmed death ligand 1 expression in hepatocellular carcinoma. Hepatol Commun 2020 Dec 30. https://doi.org/10.1002/hep4.1659. [Epub ahead of print]
15) Itoh S, Shirabe K, Matsumoto Y, Yoshia S, Muto J, Harimoto N, et al. Effect of body composition on outcomes after hepatic resection for hepatocellular carcinoma. Ann Surg Oncol 2014;21:3063-3068.
16) Chen J, Yu Y, Ji T, Ma R, Chen M, Li G, et al. Clinical implication of Keap1 and phosphorylated Nrf2 expression in hepatocellular carcinoma. Cancer Med 2016;5:2678-2687.
17) Lacher SE, Levings DC, Freeman S, Slattery M. Identification of a functional antioxidant response element at the HIFPA1 locus. Redox Biol 2018;19:401-411.
18) Barsoum IB, Koti M, Siemens DR, Graham CH. Mechanisms of hypoxia-mediated immune escape in cancer. Cancer Res 2014;74:7185-7190.
19) DeNicola GM, Chen P-H, Mullarky E, Sudderth JA, Hu Z, Wu D, et al. NRF2 regulates serine biosynthesis in non-small cell lung cancer. Nat Genet 2015;47:1475-1481.
20) Kitamura H, Motohashi H. NRF2 addiction in cancer cells. Cancer Sci 2018;109:900-911.
21) Kito Y, Baba Y, Nakagawa S, Miyake K, Iwatsuki M, Ishimoto T, et al. Nrf2 promotes osseopagical cancer cell proliferation via metabolic reprogramming and detoxification of reactive oxygen species. J Pathol 2018;244:346-357.
22) Lu Y, Shen T, Yang H, Gu W. Ruthenium complexes induce HepG2 human hepatocellular carcinoma cell apoptosis and inhibit cell migration and invasion through regulation of the Nrf2 pathway. Int J Mol Sci 2016;17:775.
23) Homma S, Ishii Y, Morishima Y, Yamadori T, Matsuno Y, Haraguchi N, et al. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res 2009;15:3423-3432.
24) Singh A, Boldin-Adamsky S, Thimmulappa RK, Rath SK, Ashush H, Coulter J, et al. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res 2008;68:7975-7984.
25) Luadmnn MH, Angelova PR, Zhang Y, Abramov AY, Dinkova-Kostova AT. Nrf2 affects the efficiency of mitochondrial fatty acid oxidation. Biochem J 2014;457:415-424.
26) Yuan P, Yang T, Mu J, Zhao J, Yang YI, Yan Z, et al. Circadian clock gene NPAS2 promotes reprogramming of glucose metabolism in hepatocellular carcinoma cells. Cancer Lett 2020;469:498-509.
27) Huang C, Li Y, Li Z, Xu Y, Li NA, Ge YL, et al. LIMIS1 promotes pancreatic cancer cell survival under oxygen-glucose deprivation conditions by enhancing HIF1α protein translation. Clin Cancer Res 2019;25:4091-4103.
28) Yeung SJ, Pan J, Lee MH. Roles of p53, MYC and HIF-1 in regulating glycolysis—the seventh hallmark of cancer. Cell Mol Life Sci 2008;65:3981-3999.
29) Torizuka T, Tamaki N, Kasagi K, Misaaki T, Kawamoto M, Taguchi H, et al. Myocardial oxidative metabolism in hypertensive patients assessed by PET with carbon-11-acetate. J Nucl Med 1995;36:1981-1986.
30) Caracó C, Aloj L, Chen LY, Chou JY, Eckelman WC. Cellular release of [18F]fluoro-2-deoxyglucose as a function of the glucose-6-phosphatase enzyme system. J Biol Chem 2000;275:18489-18494.
31) Izuishi K, Yamamoto Y, Mori H, Kameyama R, Fujihara S, Masaki T, et al. Molecular mechanisms of [18F]fluorodeoxyglucose accumulation in liver cancer. Oncol Rep 2014;31:701-706.
32) Paudyal B, Paudyal P, Oriuchi N, Tsushima Y, Nakajima T, Endo K. Clinical implication of glucose transport and metabolism evaluation by 18F-FDG PET in hepatocellular carcinoma. Int J Oncol 2008;33:1047-1054.
33) Gong W, Song Q, Lu X, Gong W, Zhao J, Min P, et al. Paclitaxel induced B7–H1 expression in cancer cells via the MAPK pathway. J Chemother 2011;23:295-299.
34) Jiang X, Zhou J, Giobbie-Hurder A, Wargo J, Hodi FS. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res 2013;19:598-609.
35) Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, et al. Oncogenic kinase NPM/ALK induces through STAT3 pathway of immunosuppressive protein CD274 (PD-1/L1, B7–H1). Proc Natl Acad Sci U S A 2008;105:20852-20857.
36) Yagawa K, Itoh S, Yoshizumi T, Iseda N, Tomiyama T, Morinaga A, et al. CMTM6 stabilizes PD-L1 expression and is a new prognostic impact factor in hepatocellular carcinoma. Hepatol Commun 2021;5:334-348.
37) Pollizzi KN, Powell JD. Integrating canonical and metabolic signalling programmes in the regulation of T cell responses. Nat Rev Immunol 2014;14:435-446.
38) Noman MZ, Chouaib S. Targeting hypoxia at the forefront of anticancer immune responses. Oncoimmunology 2014;3:e954463.
39) Sacher AG, Gandhi L. Biomarkers for the clinical use of PD-1/PD-L1 inhibitors in non-small-cell lung cancer: a review. JAMA Oncol 2016;2:1217-1222.

Author names in bold designate shared co-first authorship.

Supporting Information

Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1002/hep4.1838/suppinfo.